Related Experiment Video
Updated: Sep 19, 2025

A Patient-Derived Xenograft Model for Venous Malformation
Published on: June 15, 2020
Theragnostic approach of venous malformations in 2025: Similarities and differences with oncology advances
A Dompmartin1, J Méry de Montigny1, J M L'Orphelin1
1Department of Dermatology, CHU Caen Normandy, Caen, France.
Background:
VMs are congenital vascular anomalies are often the result of genetic mutations. Advances in genetics have revealed that certain Venous malformations (VMs) share mutations with cancers, specifically in the PI3K/AKT/mTOR proliferative pathways. This discovery has paved the way for targeted treatments, similar to those used in oncology. We aim to explore differences between VMs and cancers, particularly in therapeutic and diagnostic approaches.
Material And Methods:
We performed a systematic review of literature, up to June 2024. Articles has been classified in 3 topics: Clinical advances and prospects; Genomic concern and proliferation pathway and Therapeutics and issues: neoadjuvant strategy, adjuvant strategy. The primary outcome was to make comparison between issues in oncology and VMs.
Discussion:
We identified genetic implications as, in some hereditary cases of VMs, the "two-hit" mechanism involves both a germline and a somatic mutation in the same gene, resulting in loss of function and the manifestation of the malformation. Regarding the Therapeutic Strategies and Comparison with Oncology, adjuvant and neoadjuvant seem to be promising in VMs. Lastly, treatment acceptability is a key issue for VM patients: tolerance to the side effects of anticancer drugs used for VMs is a major concern.
Conclusion:
Wile VMs and cancers share some proliferative pathways and therapeutic targets, they differ in their growth dynamics and impact on surrounding tissues. The management of VMs is increasingly approached as a "chronic disease," similar to oncology, but the benefit-risk balance and quality of life remain specific concerns.
Insights
Venous malformations (VMs) share genetic pathways with cancers, enabling targeted therapies. However, differences in growth and patient tolerance to treatments necessitate individualized management strategies, balancing efficacy with quality of life.
Area of Science:
- Vascular anomalies
- Genetics
- Oncology
Background:
- Venous malformations (VMs) are congenital vascular anomalies often linked to genetic mutations.
- Certain VMs share mutations in proliferative pathways (PI3K/AKT/mTOR) with cancers.
- This genetic overlap suggests potential for targeted, oncology-inspired treatments.
Purpose of the Study:
- To explore the distinctions between VMs and cancers.
- To compare therapeutic and diagnostic strategies for VMs and cancers.
- To highlight the unique challenges in VM management.
Main Methods:
- Systematic literature review up to June 2024.
- Classification of articles into clinical advances, genomic pathways, and therapeutics.
- Primary outcome: Comparison of oncology and VM issues.
Main Results:
- Identified the "two-hit" mechanism (germline and somatic mutation) in hereditary VMs.
- Adjuvant and neoadjuvant strategies show promise for VM treatment.
- Patient tolerance to anti-cancer drug side effects is a significant concern for VMs.
Conclusions:
- VMs and cancers share proliferative pathways but differ in growth dynamics and tissue impact.
- VM management is increasingly viewed as a chronic disease model, akin to oncology.
- Benefit-risk balance and patient quality of life are critical considerations specific to VMs.
Related Concept Videos
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Varicose Veins I: Introduction
Venous Thrombosis I: Introduction
Veins of Head and Neck
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
Venous Thrombosis IV: Nursing Management

